PMC_AZ_Biotechnologie_210x99_GB.indd

First Page		Document Content
Date: 2012-08-02 09:23:55 Medicine Pharmaceutical sciences Emerging technologies Evidence-based medicine Personalized medicine Personal genomics Pharmaceutical industry Trastuzumab Roche Diagnostics Genomics Pharmacology Biology		PMC_AZ_Biotechnologie_210x99_GB.indd Add to Reading List Source URL: www.bcnp-consultants.com Download Document from Source Website File Size: 718,17 KB Share Document on Facebook

	Biocon Limited: Q1 FY17 Earnings Call Transcript July 22, 2016 Participants from Biocon’s Senior Management Team Kiran Mazumdar Shaw: Chairperson and Managing Director Arun Chandravarkar: CEO & Jt. Managing Director DocID: 1qxjl - View Document
	Press Release Mylan & Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency BENGALURU, India and HERTFORDSHIRE, England/PITTSBURGH, USA, July 21, 20 DocID: 1q6vz - View Document
	Patientinformation – tillæg til DBCG 2015-b,t og 2015-d,t (Trastuzumab) Antistofbehandling af brystkræft efter operation Denne information supplerer vores mundtlige information om den behandling, vi anbefaler dig. I DocID: 1pKwx - View Document
	FINAL Press Release Biocon Reports a Strong Q1FY17 Revenues at Rs 952 Crore, up by 11 %; EBITDA Up 15% to Rs 271 Crore DocID: 1pawe - View Document
	Investor Presentation June 2016 BSE: 532523 │ NSE: BIOCON │ REUTERS: BION.NS │ BLOOMBERG: BIOS IN │ WWW.BIOCON.COM DocID: 1oSV0 - View Document